



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,337	09/17/2003	Michael P. Dwyer	OC01629K	4125
24265	7590 12/27/2005		EXAM	INER
SCHERING-PLOUGH CORPORATION			WARD, PAUL V	
PATENT DEPARTMENT (K-6-1, 1990) 2000 GALLOPING HILL ROAD		990)	ART UNIT	PAPER NUMBER
	ΓH, NJ 07033-0530		1623	

DATE MAILED: 12/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/664,337	DWYER ET AL.			
		Examiner	Art Unit			
		PAUL V. WARD	1623			
Period for	The MAILING DATE of this communication ap Reply	pears on the cover sheet with the c	orrespondence address			
WHICH - Extension - Extension - If NO per - Failure - Any rep	RTENED STATUTORY PERIOD FOR REPLIEVER IS LONGER, FROM THE MAILING Dons of time may be available under the provisions of 37 CFR 1. (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be time I will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)□ R	desponsive to communication(s) filed on					
<i>,</i> —		is action is non-final.				
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
<i>,</i> —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositio	n of Claims		•			
4) Claim(s) 1-28 is/are pending in the application.						
48	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□ C	5) Claim(s) is/are allowed.					
6)□ C	Claim(s) is/are rejected.					
7) 🗌 C	Claim(s) is/are objected to.					
8) 🛛 C	claim(s) <u>1-28</u> are subject to restriction and/or	election requirement.				
Applicatio	n Papers					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority un	der 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice 3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	·			

Art Unit: 1623

DETAILED ACTION

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. The compounds and compositions according to claim 1 of Formula III, wherein R³ contains a heteroaryl/heterocyclyl moiety. These are classifiable in class 546, subclass various.
- II. The compounds and compositions according to claim 1 of Formula III, wherein R³ contains a non-heteroaryl/non-heterocyclyl moiety. These are classifiable in class 546, subclass 112+.
- III. The method of treating according to claims 17-25, wherein R³ contains a heteroaryl/heterocyclyl moiety. The claims are drawn to a method of treatment that is classifiable in class 514.
- IV. The method of treating according to claims 17-25, wherein R³ contains a non-heteroaryl/non-heterocyclyl moiety. The claims are drawn to a method of treatment that is classifiable in class 514.

The claims are drawn to a method of treatment that is classifiable in class 514.

Inventions of Group I-II and III-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process for using the product as claimed can be practiced with another materially different product, such as protein kinase inhibitors.

The inventions of Groups I-IV are separate and patentably distinct because there is no patentable co-action among them and a reference anticipating one member will not render another obvious.

Page 3

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different classification, a search of the four groups designated above would impose an undue burden upon the examiner, and restriction for examination purposes as indicated is proper.

A telephone call was made to P. Kalyanaraman on December 12, 2005, to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is requested to <u>elect a specifically disclosed species</u> of the invention to be examined for search purposes.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is 571-272-2909. The examiner can normally be reached on M-F 8 am to 4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-2/17-9197 (toll-free).

Jamés O. Wilson

Taulls

Supervisory Patent Examiner Technology Center 1600